Your session is about to expire
← Back to Search
ARV-110 for Prostate Cancer (mCRPC Trial)
mCRPC Trial Summary
This trial is testing a new cancer drug in men who have prostate cancer that has spread and progressed despite treatment with other drugs. The study will assess how well the new drug is tolerated and how safe it is.
mCRPC Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowmCRPC Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.mCRPC Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am currently on hormone therapy for cancer or have had an orchiectomy.My prostate cancer has worsened after two treatments, including abiraterone or enzalutamide.I have taken 1 or 2 treatments like enzalutamide or abiraterone for prostate cancer.I have had only one type of advanced hormone therapy for my prostate cancer.I have never received chemotherapy.I have had only one chemotherapy treatment for both early and advanced prostate cancer.My prostate cancer is advanced, has spread, and does not respond to hormone therapy.My prostate cancer is worsening despite treatment.This refers to a specific subgroup of participants for the second phase of the study.I am a man and at least 18 years old.
- Group 1: ARV-110
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many venues are currently hosting this research endeavor?
"This trial currently has 100 available slots across multiple sites, including Tennessee Oncology - Skyline in Nashville, Tennessee Oncology in Hendersonville and Florida Cancer Specialists - North - St. Anthony's in Saint Petersburg, alongside numerous other clinics."
Are there any opportunities presently available to join this experiment?
"As per the data on clinicaltrials.gov, this medical trial is still open and recruiting patients. It was first advertised in March of 2019 and its details were most recently amended in November 2021."
What beneficial results should we anticipate from this research?
"The primary goal of this experiment, which is set to conclude in 28 days time, will be the evaluation of ARV-110's clinical anti-tumor activity when dealing with patients suffering from mCRPC (PSA measured PCWG and RECIST). Secondary objectives involve assessing its Anti-Tumor Activity based on duration response over the entire population, as well as subsets separated by their mutational status. Further PK parameters such as Cmin and Tmax are also going to be evaluated after single dose administrations, or multiple once/twice daily doses."
How many participants is the research team recruiting for this project?
"This clinical trial necessitates 250 individuals, meeting the prerequisites for inclusion in the study. Interested participants can visit either Tennessee Oncology - Skyline in Nashville or Tennessee Oncology in Hendersonville to join this research endeavour."
Share this study with friends
Copy Link
Messenger